Last reviewed · How we verify
Carboplatin (adjuvant）
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells. Used for Adjuvant treatment of various solid tumors (specific indication dependent on trial design).
At a glance
| Generic name | Carboplatin (adjuvant） |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. This leads to apoptosis of cancer cells. As an adjuvant therapy, it is administered after primary treatment (surgery or radiation) to eliminate residual micrometastatic disease and improve overall survival.
Approved indications
- Adjuvant treatment of various solid tumors (specific indication dependent on trial design)
Common side effects
- Myelosuppression (thrombocytopenia, neutropenia, anemia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Allergic reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: